ANVS Research | Milton Maxwell

ANVS

Annovis Bio, Inc.

3.9300

+0.1500+3.97%

Dec 16, 4:00:02 PM EST

Upcoming Earnings

Report date

≈ -/-

Earnings Call Transcripts

This Quarter (Q1 '26)

No earnings call transcript available yet

Last Quarter (Q4 '25)

No earnings call transcript available

Key Stats

Market Cap

104.16M

P/E (TTM)

Basic EPS (TTM)

-1.43

Dividend Yield

Recent Filings

8-K

CFO departs; CEO named acting

3/25/26Mar 25, 2026

Annovis Bio's CFO Mark Guerin departed effective March 23, 2026, with no disagreements over operations or policies. CEO Maria Maccecchini steps in as Acting CFO until a permanent replacement. Smooth transition. Leadership shift tests interim stability amid biotech pressures.

8-K

2025 results: Phase 3 advances

3/16/26Mar 16, 2026

Annovis Bio reported 2025 results, with R&D expenses rising to $25.2M from $20.0M amid Phase 3 AD trial launch and 65% enrollment across 83 U.S. sites. Cash hit $19.5M, funding ops into Q3 2026. PD OLE study underway; patents extend to 2047. Progress accelerates, yet cash burn persists.

10-K

FY2025 results

3/13/26Mar 13, 2026

Annovis Bio posted FY2025 net loss of $28.9M on $29.7M operating expenses, up from $24.6M loss and $26.7M opex in FY2024, driven by $25.2M R&D (vs $20.0M) as Phase 3 AD trial ramped in February 2025, burning $10.6M in H2 AD costs while PD program added $1.5M. No revenue; cash fell to $19.5M from $10.6M despite $34.6M equity raises, funding into Q3 2026 amid going concern warning. Year-end shares hit 27.2M after offerings; warrant liability dipped to $0.6M. Clinical momentum builds with AD topline due H2 2026, but trial delays could stall funding.

8-K

DSMB clears Alzheimer's Phase 3

2/12/26Feb 12, 2026

Annovis Bio secured DSMB approval on February 12, 2026, confirming buntanetap's safety at 6 months in its pivotal Phase 3 Alzheimer's trial, now 40% enrolled. No concerns flagged; data mirrors Parkinson's study, potentially supporting combined FDA submission. Trial advances uninterrupted. First efficacy readout due early 2027.

8-K

AD Phase 3 at 40% enrolled

1/28/26Jan 28, 2026

Annovis Bio disclosed its January 28, 2026 webinar, highlighting $19m cash (debt-free) as of December 31, 2025 and 26.5m shares outstanding. Pivotal Phase 3 early AD trial has enrolled 40% of 760 patients across 83 sites, targeting full recruitment by spring 2026; PD open-label extension screening started with 500-700 patients planned. Buntanetap consistently cuts neurotoxic biomarkers. Trials advance swiftly.

About

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer's disease, as well as in phase 3 to treat parkinson's disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial to treat later stages of alzheimer's disease and dementia. The company was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.

CEO

Dr. Maria L. Maccecchini Ph.D.

IPO

1/29/2020

Website

https://www.annovisbio.com

Employees

Sector

Healthcare

Industry

Biotechnology